Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Market outlook cautious as FIIs, global risks keep investors on edge : Sunil Subramaniam
27/09/2025
HSBC picks 11 stocks to ride FII return after 12-month absence. Do you own any ?
27/09/2025
BMW Ventures IPO allotment soon. Check GMP, status, and other details
27/09/2025
Crypto ETFs set to flood US market as regulator streamlines approvals
27/09/2025
Skin in the game matters : Samir Arora suggests investors to question fund managers on personal exposure
27/09/2025
Concurrent Losers : 10 Nifty stocks decline for 5 consecutive sessions
27/09/2025
